{"id":"https://openalex.org/W2043731616","doi":"https://doi.org/10.1016/j.antiviral.2011.03.131","title":"In Vitro Combination Therapy with Tegobuvir (GS-9190) is Highly Efficient in Curing Cells from HCV Replicon and in Delaying/Preventing the Development of Antiviral Resistance","display_name":"In Vitro Combination Therapy with Tegobuvir (GS-9190) is Highly Efficient in Curing Cells from HCV Replicon and in Delaying/Preventing the Development of Antiviral Resistance","publication_year":2011,"publication_date":"2011-05-01","ids":{"openalex":"https://openalex.org/W2043731616","doi":"https://doi.org/10.1016/j.antiviral.2011.03.131","mag":"2043731616"},"language":"en","primary_location":{"id":"doi:10.1016/j.antiviral.2011.03.131","doi":"https://doi.org/10.1016/j.antiviral.2011.03.131","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.antiviral.2011.03.131","pdf_url":null,"source":{"id":"https://openalex.org/S137372404","display_name":"Antiviral Research","issn_l":"0166-3542","issn":["0166-3542","1872-9096"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052667034","display_name":"Inge Vliegen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I24156275","display_name":"Rega Institute for Medical Research","ror":"https://ror.org/03w5j8p12","country_code":"BE","type":"facility","lineage":["https://openalex.org/I24156275"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Inge Vliegen","raw_affiliation_strings":["Rega Institute, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rega Institute, Leuven, Belgium","institution_ids":["https://openalex.org/I24156275"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056476810","display_name":"Jan Paeshuyse","orcid":"https://orcid.org/0000-0003-2396-354X","observed_orcids":["https://orcid.org/0000-0003-2396-354X"]},"institutions":[{"id":"https://openalex.org/I24156275","display_name":"Rega Institute for Medical Research","ror":"https://ror.org/03w5j8p12","country_code":"BE","type":"facility","lineage":["https://openalex.org/I24156275"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Jan Paeshuyse","raw_affiliation_strings":["Rega Institute, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rega Institute, Leuven, Belgium","institution_ids":["https://openalex.org/I24156275"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113785839","display_name":"I\u2010hung Shih","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I-hung Shih","raw_affiliation_strings":["Gilead Sciences, Inc., Foster City, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Inc., Foster City, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010598506","display_name":"Gerhard P\u00fcrstinger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I190249584","display_name":"Universit\u00e4t Innsbruck","ror":"https://ror.org/054pv6659","country_code":"AT","type":"education","lineage":["https://openalex.org/I190249584"]}],"countries":["AT"],"is_corresponding":false,"raw_author_name":"Gerhard P\u00fcrstinger","raw_affiliation_strings":["University of Innsbruck, Innsbruck, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Innsbruck, Innsbruck, Austria","institution_ids":["https://openalex.org/I190249584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038619028","display_name":"Steven S. Bondy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven Bondy","raw_affiliation_strings":["Gilead Sciences, Inc., Foster City, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Inc., Foster City, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063493697","display_name":"William A. Lee","orcid":"https://orcid.org/0000-0002-2933-9468","observed_orcids":["https://orcid.org/0000-0002-2933-9468"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William A. Lee","raw_affiliation_strings":["Gilead Sciences, Inc., Foster City, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Inc., Foster City, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113612192","display_name":"Weidong Zhong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Weidong Zhong","raw_affiliation_strings":["Gilead Sciences, Inc., Foster City, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Inc., Foster City, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089010495","display_name":"Johan H. Neyts","orcid":"https://orcid.org/0000-0002-0033-7514","observed_orcids":["https://orcid.org/0000-0002-0033-7514"]},"institutions":[{"id":"https://openalex.org/I24156275","display_name":"Rega Institute for Medical Research","ror":"https://ror.org/03w5j8p12","country_code":"BE","type":"facility","lineage":["https://openalex.org/I24156275"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Johan Neyts","raw_affiliation_strings":["Rega Institute, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rega Institute, Leuven, Belgium","institution_ids":["https://openalex.org/I24156275"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5052667034"],"corresponding_institution_ids":["https://openalex.org/I24156275"],"apc_list":{"value":4160,"currency":"USD","value_usd":4160},"apc_paid":null,"fwci":0.2028,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.63895886,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"90","issue":"2","first_page":"A65","last_page":"A65"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11495","display_name":"Animal Virus Infections Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1103","display_name":"Animal Science and Zoology"},"field":{"id":"https://openalex.org/fields/11","display_name":"Agricultural and Biological Sciences"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hcv-replicon","display_name":"HCV replicon","score":0.7599999904632568},{"id":"https://openalex.org/keywords/combination-antiviral-therapy","display_name":"combination antiviral therapy","score":0.7680000066757202},{"id":"https://openalex.org/keywords/antiviral-resistance","display_name":"antiviral resistance","score":0.9330000281333923},{"id":"https://openalex.org/keywords/hepatitis-c-virus","display_name":"hepatitis C virus","score":0.9290000200271606},{"id":"https://openalex.org/keywords/ns5a-inhibitors","display_name":"NS5A inhibitors","score":0.5130000114440918}],"concepts":[{"id":"https://openalex.org/C18103114","wikidata":"https://www.wikidata.org/wiki/Q1720369","display_name":"Replicon","level":4,"score":0.8673689961433411},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.7206438183784485},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.5591675639152527},{"id":"https://openalex.org/C2993512173","wikidata":"https://www.wikidata.org/wiki/Q846227","display_name":"Antiviral therapy","level":4,"score":0.5057947635650635},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.41092225909233093},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.38835409283638},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.37869152426719666},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2722293436527252},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.2239093780517578},{"id":"https://openalex.org/C3020491458","wikidata":"https://www.wikidata.org/wiki/Q131742","display_name":"Chronic hepatitis","level":3,"score":0.1573774814605713},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13587364554405212},{"id":"https://openalex.org/C22744801","wikidata":"https://www.wikidata.org/wiki/Q172778","display_name":"Plasmid","level":3,"score":0.04363808035850525},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.041915178298950195}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.antiviral.2011.03.131","doi":"https://doi.org/10.1016/j.antiviral.2011.03.131","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.antiviral.2011.03.131","pdf_url":null,"source":{"id":"https://openalex.org/S137372404","display_name":"Antiviral Research","issn_l":"0166-3542","issn":["0166-3542","1872-9096"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9391000270843506,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W431802077","https://openalex.org/W2052099897","https://openalex.org/W1989409598","https://openalex.org/W2522785959","https://openalex.org/W2086293735","https://openalex.org/W3080752486","https://openalex.org/W2125915612","https://openalex.org/W2070616218","https://openalex.org/W2025821479","https://openalex.org/W7045589889"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2016-06-24T00:00:00"}